News

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...
Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...
Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...
Sales of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data ...